Imperial College London spin-out Circassia completes Phase II trials into grass allergy treatment.
Circassia, a life sciences spin-out of Imperial College London, has completed Phase II trials into its hay fever treatment. The UK-based company found that its grass allergy treatment for hay fever sufferers delivered significantly improved allergy symptoms over the pollen period, compared to a control group on placebos. The life sciences firm, which also developing…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
